Private Advisor Group LLC acquired a new stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) in the third quarter, Holdings Channel reports. The institutional investor acquired 4,611 shares of the company’s stock, valued at approximately $238,000.
Several other large investors also recently made changes to their positions in IONS. TRUE Private Wealth Advisors bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter valued at approximately $133,000. Rockefeller Capital Management L.P. bought a new position in shares of Ionis Pharmaceuticals during the 2nd quarter valued at approximately $156,000. Parallel Advisors LLC grew its stake in shares of Ionis Pharmaceuticals by 195.5% during the 3rd quarter. Parallel Advisors LLC now owns 3,023 shares of the company’s stock valued at $156,000 after acquiring an additional 2,000 shares during the period. Clarus Wealth Advisors grew its stake in shares of Ionis Pharmaceuticals by 200.0% during the 3rd quarter. Clarus Wealth Advisors now owns 3,600 shares of the company’s stock valued at $186,000 after acquiring an additional 2,400 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Ionis Pharmaceuticals during the 2nd quarter valued at approximately $212,000. Institutional investors own 85.87% of the company’s stock.
In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $49.54, for a total value of $619,250.00. Following the completion of the transaction, the senior vice president now directly owns 31,896 shares in the company, valued at approximately $1,580,127.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Brett P. Monia sold 34,000 shares of the company’s stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $55.00, for a total value of $1,870,000.00. Following the completion of the transaction, the chief operating officer now owns 49,841 shares of the company’s stock, valued at $2,741,255. The disclosure for this sale can be found here. Corporate insiders own 2.13% of the company’s stock.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Tuesday, November 6th. The company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. Ionis Pharmaceuticals had a negative return on equity of 1.58% and a negative net margin of 7.52%. The business had revenue of $145.40 million during the quarter, compared to the consensus estimate of $146.77 million. During the same period in the prior year, the company posted ($0.02) EPS. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, sell-side analysts expect that Ionis Pharmaceuticals Inc will post -0.24 EPS for the current fiscal year.
A number of research analysts recently issued reports on IONS shares. Piper Jaffray Companies set a $50.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, September 24th. Stifel Nicolaus cut their price objective on Ionis Pharmaceuticals from $55.00 to $48.00 and set a “hold” rating for the company in a research note on Tuesday, August 7th. ValuEngine upgraded Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. Morgan Stanley set a $45.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, October 3rd. Finally, Zacks Investment Research downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $53.50.
TRADEMARK VIOLATION WARNING: “Private Advisor Group LLC Takes $238,000 Position in Ionis Pharmaceuticals Inc (IONS)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.com-unik.info/2018/12/01/private-advisor-group-llc-takes-238000-position-in-ionis-pharmaceuticals-inc-ions.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Recommended Story: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.